| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2686 |
| Trial ID | NCT04885907 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1273|Elasomeran|Spikevax |
| Location approved | UK, Canada, Taiwan, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
| Phase | Phase4 |
| Recruitment status | Completed |
| Title | A Randomised, Blinded, Controlled Trial of a Third Dose of Moderna COVID-19 Vaccine Versus Placebo in Solid Organ Transplant Recipients |
| Year | 2021 |
| Country | Canada |
| Company sponsor | University Health Network, Toronto |
| Other ID(s) | 21-5324.0 |
| Vector information | |||
|
|||
| Cohort1: mRNA-1273 | |||||||||||
|
|||||||||||
| Cohort2: normal saline | |||||||||||
|
|||||||||||